• 1. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 2. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 5. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584

Introduction to 2-Chloro-n-isopropyl-n-(1-methyl-piperidin-4-yl)-acetamide (CAS No. 1353970-33-8)

2-Chloro-n-isopropyl-n-(1-methyl-piperidin-4-yl)-acetamide, chemically designated as 2-Chloro-n-isopropyl-n-(1-methyl-piperidin-4-yl)-acetamide, is a significant compound in the realm of pharmaceutical chemistry. This compound, identified by its CAS number CAS No. 1353970-33-8, has garnered attention due to its potential applications in the development of novel therapeutic agents. The molecular structure of this compound incorporates a chloro-substituted acetamide moiety linked to an isopropyl group and a 1-methyl-piperidin-4-yl group, which together contribute to its unique chemical properties and biological activities.

The synthesis and characterization of this compound have been subjects of extensive research, particularly in the context of designing molecules with enhanced pharmacological profiles. The presence of the chloro group in the molecular framework often enhances the lipophilicity and binding affinity of the compound, making it a valuable scaffold for drug discovery. Additionally, the piperidine ring, particularly the 1-methyl-piperidin-4-yl moiety, is known for its role in modulating receptor interactions, which is crucial for developing drugs that target specific biological pathways.

Recent advancements in medicinal chemistry have highlighted the importance of such structurally complex molecules in addressing unmet medical needs. The combination of the chloro-substituted acetamide and the piperidine derivative in 2-Chloro-n-isopropyl-n-(1-methyl-piperidin-4-yl)-acetamide presents a promising avenue for developing drugs with improved efficacy and reduced side effects. This compound has been investigated in various preclinical studies for its potential role in modulating inflammatory responses and neural signaling pathways.

In vitro studies have demonstrated that 2-Chloro-n-isopropyl-n-(1-methyl-piperidin-4-yl)-acetamide exhibits significant activity against certain enzymatic targets relevant to inflammatory diseases. The chloro group interacts with polar regions of the target proteins, enhancing binding affinity, while the piperidine moiety stabilizes the compound's conformation in solution, improving its pharmacokinetic properties. These findings are particularly intriguing given the increasing interest in targeted therapies for chronic inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease.

The compound's potential extends beyond anti-inflammatory applications. Preliminary research suggests that it may also have neuroprotective properties, making it a candidate for investigating treatments for neurodegenerative disorders like Alzheimer's disease and Parkinson's disease. The ability of 2-Chloro-n-isopropyl-n-(1-methyl-piperidin-4-yl)-acetamide to cross the blood-brain barrier is a critical factor in its potential therapeutic utility for central nervous system disorders. The presence of lipophilic groups enhances its ability to penetrate this barrier, ensuring that it can reach its target sites within the brain effectively.

The synthesis of this compound involves multi-step organic reactions that require precise control over reaction conditions to achieve high yields and purity. Advanced synthetic techniques, including catalytic hydrogenation and nucleophilic substitution reactions, are employed to construct the desired molecular framework. The use of high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) spectroscopy are essential for characterizing the intermediate and final products, ensuring their structural integrity.

The pharmacological evaluation of 2-Chloro-n-isopropyl-n-(1-methyl-piperidin-4-yl)-acetamide has been conducted using both in vitro and in vivo models. In vitro assays have revealed potent inhibitory activity against key enzymes involved in inflammatory pathways, such as cyclooxygenase (COX) and lipoxygenase (LOX). These enzymes are critical mediators of inflammation, and their inhibition can lead to significant reductions in pro-inflammatory cytokine production.

In vivo studies have further supported these findings by demonstrating that 2-Chloro-n-isopropyl-n-(1-methyl-piperidin-4-yl)-acetamide can attenuate acute inflammatory responses in animal models without causing notable side effects. The compound's ability to modulate immune cell function has been particularly noteworthy, suggesting its potential as a therapeutic agent for autoimmune diseases. Additionally, its favorable pharmacokinetic profile has been observed across multiple species tested so far, indicating good bioavailability and metabolic stability.

The development of new drugs is often hampered by issues related to drug resistance and off-target effects. However, compounds like 2-Chloro-n-isopropyl-n-(1-methyl-piperidin-4-yl)-acetamide, with their complex molecular architectures, offer a promising solution by targeting multiple pathways simultaneously or by enhancing selectivity through subtle structural modifications. This approach can help overcome resistance mechanisms and minimize side effects associated with traditional therapies.

The future direction of research on this compound includes exploring its mechanism of action at a molecular level and identifying additional therapeutic applications. Collaborative efforts between academic institutions and pharmaceutical companies are essential for translating these preclinical findings into clinical trials that can ultimately benefit patients suffering from various diseases. The growing body of evidence supporting the efficacy and safety of 2-Chloro-n-isopropyl-n-(1-methyl-piperidin-4-yl)-acetamide makes it a compelling candidate for further development as a novel therapeutic agent.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)